Hans Layman, Ph.D.

Senior Director, Translational Medicine

Dr. Hans Layman joined Federation Bio in March 2021 as the Senior Director of Translational Medicine. In this role, he leads the vivarium team conducting nonclinical research, collaborates closely with the autoimmune and oncology research programs for successful translation to clinical studies, and is spearheading the evaluation of primary and exploratory endpoints for the secondary hyperoxaluria program.

Prior to joining Federation Bio, Dr. Layman has served on and led oncology, immune-oncology and infectious disease translational programs from pre-IND through Phase 3 clinical trials. While at AstraZeneca and NewLink Genetics, his work helped steer a broad range of modalities through clinical trials including small and large molecules, cell therapies, oncolytic viruses, and cancer vaccines. He has also successfully validated numerous immunological and cell-based assays to support research and clinical programs during his tenure in pharma and CROs. Lastly, he has supported GLP-Tox enabling studies in numerous species for successful translation to the clinic.

Dr. Layman received his Ph.D. in Bioengineering from The University of Miami, Florida and conducted his postdoctoral work at the University of California, San Francisco.